Tanshinone IIA attenuates AOM/DSS-induced colorectal tumorigenesis in mice via inhibition of intestinal inflammation

Lijie Liu, Hanjing Gao, Tao Wen, Tao Gu, Shuang Zhang and Zhiyong Yuan

Department of Radiation Oncology, Tianjin Medical University Cancer Institute and Hospital, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China; Department of Oncology, First Hospital of Qinhuangdao, Qinhuangdao, China; Department of Radiation Oncology, Tianjin 4TH Centre Hospital, Tianjin, China; Medical Research Center, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China; Department of Cardiology, First Department of Qinhuangdao, Qinhuangdao, China

ABSTRACT

Context: Tanshinone IIA is a natural extract derived from a Chinese medicinal herb with multiple bioactivities; however, whether and how tanshinone IIA protects against colorectal cancer (CRC) are uncertain.

Objective: We investigated the potential beneficial effects of tanshinone IIA in a colitis-associated colorectal tumorigenesis mouse model and its underlying mechanisms.

Materials and methods: Male C57BL/6 mice were treated with azoxymethane (AOM) 10 mg/kg body weight and dextran sulphate sodium (2.5% DSS) to induce a colitis-associated cancer model. Tanshinone IIA (200 mg/kg body weight) was given to the mice intraperitoneally. After 12 weeks, all mice were sacrificed to measure tumour formation, intestinal permeability, neutrophil infiltration, and colonic inflammation. In addition, whether tanshinone IIA has inhibitory effects on neutrophil activation was determined through in vitro investigations.

Results: We observed that tanshinone IIA significantly decreased tumour formation in AOM/DSS-treated mice compared to AOM/DSS-treated alone mice (0.266 ± 0.057 vs. 0.78 ± 0.153, p = 0.013). Tanshinone IIA also decreased intestinal permeability compared to that in AOM/DSS-treated alone mice (3.12 ± 0.369 vs. 5.06 ± 0.597, p = 0.034) and consequently reduced neutrophil infiltration of the colonic mucosa (53.25 ± 8.85 vs. 107.6 ± 13.09, p = 0.014) as well as intestinal inflammation in mice. Mechanistically, tanshinone IIA downregulated the NF-κB signalling pathway in the colonic tumours of AOM/DSS-treated mice. In vitro assays further validated that tanshinone IIA suppressed LPS-induced neutrophil activation.

Conclusion: These data suggest that tanshinone IIA alleviates colorectal tumorigenesis through inhibition of intestinal inflammation. Tanshinone IIA may have a therapeutic potential for CRC in clinical practice.

Introduction

Colorectal cancer (CRC) is one of the most common cancers worldwide and a leading cause of cancer-related death (Siegel et al. 2019). The clinical treatment options for CRC include surgery, chemotherapy, radiotherapy, and targeted therapy. Despite current advances and improvements in the early screening and therapy of CRC, the overall survival rates of CRC patients are discouragingly low (Siegel et al. 2019). Many risk factors have been associated with the aetiology of CRC; of these, chronic intestinal inflammation is a major risk factor (Beaugerie et al. 2013; Johnson et al. 2013; Lutgens et al. 2013). Accumulating evidence has demonstrated that people with inflammatory bowel disease (IBD), including ulcerative colitis and Crohn’s disease, have a 5- to 10-fold increase in the risk of developing CRC (Deng et al. 2019). Persistent inflammation alters immune responses, promotes the release of pro-inflammatory cytokines and growth factors, and further facilitates cell proliferation and tumorigenesis (Malgorzata et al. 2013; West et al. 2015; Yahyapour et al. 2018; Wang et al. 2020). Therefore, anti-inflammatory strategies in the intestine may be an attractive way to prevent and treat CRC and are worthy of more investigation.

Tanshinone IIA (Figure 1(A)) is a natural extract derived from Danshen (Salviae miltiorrhizae Bunge [Lamiaceae]), a Chinese medicinal herb identified by the Chinese Pharmacopoeia that is currently used to treat stroke, cardiovascular disorders, Alzheimer’s disease, diabetes, etc. with clinical efficacy (Gao et al. 2012; Robertson et al. 2014; Ji et al. 2017). Tanshinone IIA has exhibited wide-ranging effects such as its anti-angiogenic, antioxidative, anti-inflammatory, and antitumor activities (Shu et al. 2016). Regarding its antitumor roles, tanshinone IIA has been documented to have therapeutic effects in oesophageal, colorectal, lung, prostate, and gastric cancers by modulating cancer cell growth, apoptosis, invasion, migration, and drug resistance (Yang et al. 2005; Jieensinue et al. 2018; Gao et al. 2020). Tanshinone IIA may act as an adjuvant drug to inhibit the progression of human cancers in clinical practice (Zhang et al. 2019). To date, the effects and mechanisms of tanshinone IIA on colitis-associated CRC have not been fully investigated. In this...
study, we used a well-established azoxymethane (AOM)/dextran sulphate sodium (DSS)-induced murine CRC model to examine whether tanshinone IIA has a protective role and the mechanisms involved. We hypothesised that tanshinone IIA may protect against colitis-associated colorectal tumorigenesis through amelioration of intestinal inflammation in mice.

Materials and methods

Animals

Male C57BL/6 mice (aged 8–10 weeks) were purchased from the Laboratory Animal Centre of Tianjin Medical University (Tianjin, China). The mice were kept in standard housing cages under specific pathogen free conditions. All experimental procedures were reviewed and approved by the Tianjin Medical University Animal Care and Use Committee (approval No. ACUC-19-122) and were carried out in accordance with the NIH Guidelines for the Care and Use of Laboratory Animals.

AOM/DSS-induced colorectal tumour mouse model

A murine colitis-associated colorectal tumour model was prepared as previously described (An et al. 2007; Li et al. 2019). The mice were randomly divided into three groups (n = 10): AOM/DSS treatment, AOM/DSS plus tanshinone IIA, and control. Briefly, the mice were given an intraperitoneal injection of AOM (10 mg/kg body weight; Sigma-Aldrich, USA) on the first day and then maintained on regular water and diet for one week. After that, the mice were fed with 2.5% DSS (40 kDa; Sigma-Aldrich) in their drinking water for one week and then received normal water for two weeks. This cycle was repeated three times. Tanshinone IIA (Sigma-Aldrich) was dissolved in DMSO and intraperitoneally administered to the mice (200 mg/kg body weight) every 2 days during induction of the CRC model (Figure 1(B)). Control mice were treated with vehicle or tanshinone IIA alone. Body weight was measured weekly. The mice were sacrificed at 12 weeks, and the colons were removed for further analysis. Each colon was cut open longitudinally and examined for tumour numbers and sizes. We obtained tumour volumes by measuring the length (l) and the width (w) and calculating the volume (V = lw²/2), as previously described (An et al. 2007). Parts of the colonic tissues were fixed in 10% neutral buffered formalin, processed, and embedded in paraffin. The sections (5 μm thick) were prepared and stained with haematoxylin and eosin using standard techniques. Fresh colonic tissue lysates were also collected for western blot or other analysis.

Assay to detect intestinal integrity

We assayed intestinal integrity in mice as described previously (Liu et al. 2016). In brief, mice were given 200 μL of FITC-dextran (4kDa, 500 mg/kg body weight, Sigma-Aldrich, USA) by gavage. After 4 h, serum samples were collected from the mice and assessed using a fluorimeter. Serial dilutions of FITC-dextran were used to generate a standard curve, and the serum concentrations of FITC-dextran in the mice were calculated accordingly.

Measurement of colonic neutrophil infiltration and inflammation

To detect infiltrated neutrophils, colons were dissected from the mice and fixed in 4% paraformaldehyde at 4 °C overnight, followed by cryoprotection in 20% sucrose, and then embedded in a mixture of OCT compound and tissue freezing medium. The 8 μm cryosections were stained with rat anti-mouse Ly6G (2 μg/mL, Abcam) overnight at 4 °C and then incubated with FITC-conjugated donkey anti-rat IgG (1:200) for 1 h at room temperature. The sections were mounted with Vectashield mounting medium and examined with a fluorescence microscope.

We also measured the levels of colonic myeloperoxidase (MPO), reactive oxygen species (ROS), and multiple cytokines to characterise intestinal inflammation in AOM/DSS-treated mice. Briefly, colon tissues were dissected, rinsed with cold PBS, and cut into small pieces. The samples were homogenised in 50 mM phosphate buffer, and centrifuged at 10,000 g for 20 min at 4 °C to obtain the supernatant. The MPO and ROS levels were assayed using commercially available kits, according to the manufacturer’s protocols. In addition, we quantified a panel of multiple cytokines (IL-1β, IL-6, IL-10, IL-17A, IFN-γ, and TNF-α) in the colonic homogenates using the ProcartaPlexTM Multiplex Immunoassay (Luminex) on a Bioplex-200 system with Bioplex Manager 5.0 software, according to the manufacturer’s protocol.

Western blotting

The colonic tissues of mice were lysed in RIPA lysis buffer. After centrifugation at 10,000 g for 20 min at 4 °C, the supernatants
were collected, and protein concentrations were measured using a BCA assay kit (Thermo Fisher, MA, USA). Electrophoresed samples were separated by SDS-PAGE and transferred to PVDF membranes (Millipore, MA, USA) and blocked using 5% fat-free milk for 1 h at room temperature. After being washed in PBST, the membranes were incubated with primary antibodies at 4°C overnight. Then, the membranes were washed three times in PBST before the addition of HRP-labeled secondary antibodies. The signals were detected by the application of chemiluminescent HRP substrate (Millipore) on a Bio-Rad imaging system (Bio-Rad ChemiDoc MP). The primary antibodies against the following (Cell Signalling) were used: NF-κB p65, phospho-NF-κB p65, 1×β2, phospho-1×B2, and β-actin.

Assay for in vitro neutrophil activation

We collected peripheral blood from the mice in heparin-coated tubes by cardiac puncture and pooled the peripheral blood. After the lysis of red blood cells, we isolated neutrophils using the Ficoll gradient centrifugation method. Neutrophil purity was assessed using Wright-Giemsa staining and shown to be greater than 95% (Liu et al. 2016). We stimulated neutrophil activation by the addition of LPS (100 ng/mL) in DMEM with 10% FBS for 3 h. Tanshinone IIA was dissolved in DMSO and added to neutrophils with serial concentrations (10, 20, 40 μM). After treatment, the cells were harvested and homogenised in a lysis buffer. Then the homogenates were centrifuged at 10,000×g for 15 min at 4°C, and the supernatants were analysed for MPO, ROS, and multiple cytokines (IL-1β, IL-6, IL-10, IL-17A, IFN-γ and TNF-α) as described above.

Statistical analysis

All data were expressed as the mean ± SD. Student’s t-test (unpaired, 2-tailed) was used to analyse the statistical significance of differences between groups. The results were considered statistically significant when p < 0.05. All statistical analyses were calculated using GraphPad Prism.

Results

Tanshinone IIA alleviated AOM/DSS-induced colorectal tumorigenesis in mice

In this study, we used a well-established AOM/DSS murine model that mimics chronic intestinal inflammation to investigate whether tanshinone IIA has a therapeutic role in colitis-associated colorectal tumorigenesis. We observed that in AOM/DSS-treated mice, the colon and rectum developed multiple tumours at the experimental endpoint. Histological examination revealed obvious crypt destruction, architectural and cytological atypia, and massive inflammatory cell infiltration, as compared to the control mice receiving vehicle or tanshinone IIA alone, which did not exhibit any aberrant features. Most tumours exhibited extensive high-grade dysplasia or intramucosal carcinoma. In contrast, cotreatment with tanshinone IIA markedly reduced tumour volumes and caused a dramatic improvement in crypt structure and tumour formation in AOM/DSS-treated mice; most tumours exhibited low-grade dysplasia and much less infiltration of inflammatory cells (Figure 2). These data suggested that tanshinone IIA could significantly ameliorate colitis-associated colorectal tumorigenesis in mice.

Tanshinone IIA ameliorated intestinal permeability and neutrophil infiltration in AOM/DSS-treated mice

Next, we sought to explore the mechanisms by which tanshinone IIA protects against colorectal tumorigenesis. Intestinal permeability is frequently impaired during the course of colitis-associated colorectal cancer, which may in turn provoke inflammatory cell infiltration and enhance intestinal inflammation in a vicious cycle (Williams et al. 2015; Yu 2018; Becker et al. 2019). We used in vivo investigations to test whether tanshinone IIA may influence intestinal permeability. We treated the mice with FITC-dextran by gavage and measured serum concentrations of FITC-dextran to assess intestinal permeability. The results showed that serum concentrations of FITC-dextran in AOM/DSS-treated mice were drastically elevated than in the control mice, whereas cotreatment with tanshinone IIA caused a remarkable decrease in serum concentrations of FITC-dextran (Figure 3(A)), indicating that tanshinone IIA may improve intestinal permeability.

Impaired intestinal permeability leads to the infiltration of immune cells; of which, infiltrated neutrophils are an important feature in colitis-associated colorectal cancer (Hull et al. 2006; Becker et al. 2019; Lin et al. 2020). We therefore probed colonic tissues with anti-Ly6G, a specific antibody that recognises neutrophils, to characterise neutrophil infiltrates in the mucosa of AOM/DSS-treated mice. Compared to the control mice, AOM/DSS-treated mice showed a dramatic increase in Ly6G-positive cells around the mucosal area of, indicative of prominent neutrophil infiltration. In contrast, tanshinone IIA treatment significantly reduced Ly6G-positive cells in the mucosal tissues of AOM/DSS-treated mice (Figure 3(B,C)).

Tanshinone IIA attenuated intestinal inflammation in AOM/DSS-treated mice

Increased neutrophil infiltration may elicit intestinal inflammatory responses, which further contribute to colorectal tumorigenesis (Terzić et al. 2010; Park and Kim 2018). To address this question, we measured MPO, ROS, and various cytokines in the colonic tissues of AOM/DSS-treated mice to assess the extent of intestinal inflammation. The results showed that the levels of MPO, ROS, and the inflammatory cytokines (IL-1β, IL-6, IL-10, IL-17A, IFN-γ and TNF-α) were all elevated in the colonic tissues of AOM/DSS-treated mice compared with the controls, indicating the occurrence of obvious intestinal inflammation. In contrast, tanshinone IIA treatment exhibited a suppressive effect on these indices (Figure 4).

We further investigated the molecular mechanisms underlying the anti-inflammatory effects of tanshinone IIA. The NF-κB signalling pathway is well recognised to play a critical role in inflammatory diseases and tumorigenesis (Terzić et al. 2010). Persistent activation of the NF-κB pathway can promote the malignant transformation and proliferation of colonic epithelial cells (Soleimani et al. 2020). We observed that in AOM/DSS-treated mice, the levels of NF-κB signalling components (p65-NF-κB, phosphorylated p65-NF-κB, phosphorylated 1×B2) were upregulated compared with those in the control group, indicating that AOM/DSS promoted the activation of NF-κB signalling. Notably, tanshinone IIA cotreatment substantially decreased activation of the NF-κB signalling pathway, as evidenced by the reduced expression levels of both phosphorylated p65-NF-κB and 1×B2 (Figure 5). Taken together, these data suggested that
Tanshinone IIA may resolve intestinal inflammation by suppression of NF-κB pathway.

**Tanshinone IIA had an inhibitory effect on neutrophil activation in vitro**

To validate these *in vivo* investigations, we isolated mouse neutrophils and treated them with LPS for 3 h in the absence or presence of tanshinone IIA with different concentrations (10, 20, 40 μM). LPS treatment significantly increased the activation of neutrophils, as evidenced by increased levels of MPO, ROS, and multiple cytokines in the supernatant of cultured cells, whereas tanshinone IIA coinubation markedly decreased these markers in a dose-dependent manner (Figure 6). These data suggested that tanshinone IIA has an inhibitory effect on neutrophil activation, which may account for its protection against colitis-associated colorectal tumorigenesis in mice.

**Discussion**

Chronic intestinal inflammation is increasingly recognised due to its implication in the pathogenesis of CRC, which may induce the neoplastic transformation of colonic epithelial cells, promoting cellular proliferation and invasiveness, leading to the infiltration of immune cells and soluble mediators, which eventually provides a favourable microenvironment for tumour initiation and development (Park and Kim 2018; Pejin et al. 2017). Accumulating evidence has revealed that patients with inflammatory bowel disease (IBD) are at a high risk of developing CRC (Malhotra et al. 2018; Zhou et al. 2019). CRC patients are mainly treated with surgery supplemented with other therapeutic options, such as chemotherapy and radiotherapy (Johnson et al. 2013; Ganesh et al. 2019). The resolution of intestinal inflammation has been suggested as an important therapeutic strategy to prevent and treat CRC (Pejin et al. 2013; Zhao et al. 2020). To date, interest in exploring potential agents with anti-inflammatory properties for the prevention and treatment of CRC has been increasing.

Previous studies have reported that tanshinone IIA, a natural product isolated from a Chinese medicinal herb, displayed notable protective effects against a variety of inflammatory conditions including colitis (Yang et al. 2005; Liu et al. 2016). In addition, tanshinone IIA has also been frequently used as an
adjunct drug to retard the progression of many cancers (Dong et al. 2011). The tumour-suppressive effects of tanshinone IIA are thought to be attributed to its influence on cell growth, migration and invasion, and enhancement of cell apoptosis (Xing et al. 2015; Gao et al. 2020). In this study, we used an AOM/DSS-induced colitis-associated colorectal tumour model, which resembles human CRC, to evaluate whether tanshinone IIA has beneficial effects on colorectal tumorigenesis, and thereby may have potentials as a therapy in clinical practice. Our data showed that mice treated with AOM/DSS developed typical tumours in the colon and rectum; most of the epithelia exhibited moderate or severe dysplasia, irregular crypt arrangement, and inflammatory

Figure 3. Tanshinone IIA improved intestinal permeability and reduced intestinal neutrophil infiltration. (A) Serum concentrations of FITC-dextran in AOM/DSS- and AOM/DSS + tanshinone IIA-treated mice were measured to assess intestinal permeability. Error bars represent the mean ± SD (n = 10 for each group). (B) Ly6G-positive neutrophil infiltrates in colonic sections from control mice, AOM/DSS- and AOM/DSS + tanshinone IIA-treated mice. (C) Positive staining areas per high-powered microscopic field (10×) were quantified based on six sections from three independent mice from each group. Error bars indicate the mean ± SD.

Figure 4. Tanshinone IIA inhibited intestinal inflammation in AOM/DSS-treated mice. (A) Colonic MPO activity (B) Colonic ROS levels were significantly elevated in AOM/DSS-treated mice, whereas tanshinone IIA markedly reduced their levels (mean ± SD, n = 10 for each group). (C) Multiple inflammatory cytokines were increased in the colonic tissues of AOM/DSS-treated mice when compared with their levels in the controls (*p < 0.05). Tanshinone IIA treatment decreased most of the detected cytokines (IL-6, IL-17A, INF-γ, TNF-α) in mice treated with AOM/DSS (#p < 0.05).
cell infiltration of the mucosa. Notably, tanshinone IIA significantly reduced the severity of glandular hyperplasia and the extent of inflammatory cell infiltration. These results suggest that tanshinone IIA has a therapeutic effect on colitis-associated colorectal tumorigenesis, thereby suggesting its consideration as a promising agent for the prevention and treatment of CRC.

We next sought to delineate the mechanisms by which tanshinone IIA confers its protection against colorectal tumorigenesis in this model. Indeed, tanshinone IIA has been shown to be protective against a variety of inflammatory disease models, including DSS-induced colitis in mice (Zhang et al. 2015; Liu et al. 2016). DSS is a heparin-like polysaccharide that can impair epithelial integrity, thereby increasing intestinal permeability, which may further lead to immune cell infiltration and subsequent intestinal inflammation (Liu et al. 2016). Our data demonstrated robust inflammation in the colonic tissues of AOM/DSS-treated mice, as evidenced by damaged intestinal permeability, the prominent infiltration of neutrophils, a significant increase in the release of MPO and ROS and high levels of inflammatory cytokines, which may be involved in the initiation and development of colorectal tumours. Administration of tanshinone IIA significantly ameliorated intestinal inflammation in AOM/DSS-treated mice.

Furthermore, a remarkable improvement in intestinal permeability was observed, accompanied by reduced neutrophil infiltration and the decreased production of MPO, ROS and multiple inflammatory cytokines, which may largely account for the protective effects of tanshinone IIA in this model. The NF-κB signalling pathway plays a key role in colitis-associated colorectal tumorigenesis. It has been reported that activation of the NF-κB signalling pathway may be essential for the progression of colitis to cancer (Wan et al. 2019; Jiang et al. 2020).

Our results showed that AOM/DSS-treated mice exhibited elevated levels of NF-κB signalling components, consistent with...
the observed intestinal inflammation. Tanshinone IIA inhibited these increases, suggesting that it may exert anti-inflammatory effects through the inhibition of NF-κB signalling pathway.

In addition, as mentioned before, infiltrated neutrophils resulting from impaired intestinal integrity may lead to accelerated intestinal inflammation. We questioned whether tanshinone IIA exerts its anti-inflammatory effects by targeting neutrophils. We isolated and treated murine neutrophils with LPS in the presence or absence of tanshinone IIA. We found that tanshinone IIA could inhibit LPS-stimulated neutrophil activation, as demonstrated by the decreased production of MPO, ROS and inflammatory cytokines, which was consistent with the in vivo findings.

In summary, our data suggest that tanshinone IIA can be used for the prevention and treatment of colitis-associated colorectal tumorigenesis, which is likely due to its bioactivity in ameliorating intestinal inflammation by inhibition of neutrophil activation.

Disclosure statement
No potential conflict of interest was reported by the author(s).

Funding
This work was supported by National Natural Science Foundation of China [81672338].

References
An G, Wei B, Xia B, McDaniel JM, Ju T, Cummings RD, Braun J, Xia L. 2007. Increased susceptibility to colitis and colorectal tumors in mice lacking core 3−derived O-glycans. J Exp Med. 204(6):1417−1429.
Beaugerie L, Svrcek M, Seksik P, Bouvier AM, Simon T, Allez M, Brixi H, Gornet JM, Altweig R, Beau P, et al. 2013. Risk of colorectal high-grade dysplasia and cancer in a prospective observational cohort of patients with inflammatory bowel disease. Gastroenterology. 145(1):166−175.e8.
Becker J, Ott D, Diener M. 2019. Impact of sensitization and inflammation on the interaction of mast cells with the intestinal epithelium in rats. Front Physiol. 10:1−14.
Deng S, Wang A, Chen X, Du Q, Wu Y, Chen G, Guo W, Li Y. 2019. HBD inhibits the development of colitis-associated cancer in mice via the IL-6R/STAT3 signaling pathway. JIMMS. 20(5):1069.
Dong Y, Morris-Natschke SL, Lee KH. 2011. Biosynthesis, total syntheses, pharmacological potential. Nat Prod Rep. 28(3):529−542.
Ganesh K, Stadler ZK, Cercek A, Mendelsohn RB, Shia J, Segal NH. Diaz IA. 2019. Immunotherapy in colorectal cancer: rationale, challenges and potential. Nat Rev Gastroenterol Hepatol. 16(6):361−375.
Gao F, Li M, Liu W, Li W. 2020. Inhibition of EGFR signaling and activation of mitochondrial apoptosis contribute to tanshinone IIA-mediated tumor suppression in non-small cell lung cancer cells. Onco Targets Ther. 13:2757−2769.
Gao S, Liu Z, Li H, Little PJ, Liu P, Xu S. 2012. Cardiovascular actions and therapeutic potential of tanshinone IIA. Atherosclerosis. 220(1):3−10.
Hull MA, Faluyi OO, Ko CWs, Holwell S, Scott DJ, Cutliff RJ, Poulsom R, Goodfard R, Ronifer C, Markham AE, et al. 2006. Regulation of stomach cell cyclooxygenase-2 in the ApcMin/+ mouse model of intestinal tumorigenesis. Carcinogenesis. 27(3):382−391.
Ji B, Zhou F, Han L, Yang J, Fan H, Li S, Li J, Zhang X, Wang X, Chen X, et al. 2017. Sodium tanshinone IIA sultionate enhances effectiveness RT-PA treatment in acute ischemic stroke patients associated with ameliorating blood-brain barrier damage. Trans Stroke Res. 8(4):334−340.
Jiang F, Liu M, Wang H, Shi G, Chen B, Chen T, Yuan X, Zhu P, Zhou J, Wang Q, et al. 2020. Wu Mei Wan attenuates CAC by regulating gut microbiota and the NF-κB/Ile6-STAT3 signaling pathway. Biomed Pharmacother. 125:109982.
Jiensinuse S, Zhu H, Li G, Dong K, Liang M, Li Y. 2018. Tanshinone IIA reduces SW837 colorectal cancer cell viability via the promotion of mitochondrial fission by activating JNK-Mff signaling pathways. BMC Cell Biol. 19(1):21.
Johnson CM, Wei C, Ensor JE, Smolenisky DJ, Amos CI, Levin B, Berry DA. 2013. Meta-analyses of colorectal cancer risk factors. Cancer Causes Control. 24(6):1207−1222.
Li B, Wang Y, Yin L, Huang G, Xu Y, Su J, Ma L, Lu J. 2019. Glucocorticoids promote the development of azoxymethane and dextran sulfate sodium-induced colorectal carcinoma in mice. BMC Cancer. 19(1):94.
Lin L, Wang D, Qu S, Zhao H, Lin Y. 2020. MiR-370-3p alleviates ulcerative colitis-related colorectal cancer in mice through inhibiting the inflammatory response and epithelial-mesenchymal transition. Drug Des Devel Ther. 14:1127−1141.
Liu X, He H, Huang T, Lei Z, Liu F, An G, Wen T. 2016. Tanshinone IIA protects against dextran sulfate sodium (DSS-) induced colitis in mice by modulation of neutrophil infiltration and activation. Oxid Med Cell Longev. 2016:7916763.
Lugtens MWMd, van Oijen MGH, van der Heijden GJM, Vleggaar FPV, Siersma PD, Oldenburg B. 2013. Declining risk of colorectal cancer in inflammatory bowel disease: an updated meta-analysis of population-based cohort studies. Inflamm Bowel Dis. 19(4):789−799.
Malgorzata KK, Dorota D, Bartosz K, Marek B, Andrzej G. 2013. Profiles of circulating inflammatory cytokines in colorectal cancer (CRC), high cancer risk conditions, and health are distinct. Possible implications for CRC screening and surveillance. Cancer Lett. 337:107−114.
Malhotra A, Phatharacharakul P, Thongprayaon C. 2018. Risk factors for 90-day readmission in veterans with inflammatory bowel disease−Does post-discharge follow-up matter? Mil Med Res. 5(1):5−11.
Park JH, Kim JK. 2018. Pristimerin, a naturally occurring triterpenoid, attenuates tumorigenesis in experimental colitis-associated colon cancer. Phytomedicine. 42:164−171.
Pejin B, Iodice C, Bogdanovic G, Kojić V, Tesević V. 2017. Stictic acid inhibits cell growth of human colon adenocarcinoma HT-29 cells. Arab J Chem. 10:S1240−S1242.
Pejin B, Jovanovic KK, Miović M, Savić AG. 2013. New and highly potent antitumor natural products from marine-derived fungi: covering the period from 2003 to 2012. Curr Top Med Chem. 13(21):2745−2766.
Roberson AL, Holmes GR, Bojarczuk AN, Burgon J, Loynes CA, Chimen M, Sawtell AK, Hamza B, Willson J, Walmsley SR, et al. 2014. A zebrafish compound screen reveals modulation of neutrophil reverse migration as an anti-inflammatory mechanism. Sci Transl Med. 6(225):225ra29.
Shu M, Hu X, Hung Z, Huang D, Zhang S. 2016. Effects of tanshinone IIA on fibrosis in a rat model of cirrhosis through heme oxygenase-1, inflammation, oxidative stress and apoptosis. Mol Med Rep. 13(4):3036−3042.
Siegel RL, Miller KD, Jemal A. 2019. Cancer statistics, 2019. CA A Cancer J Clin. 69(1):7−34.
Soleimani A, Rahmani F, Ferns GA, Ryzhikov M, Avan A, Hassanian SM. 2020. Role of the NF-κB signaling pathway in the pathogenesis of colorectal cancer. Gene. 726:144132.
Tako G, Funakoshi-Tago M, Ohta S, Kawata H, Saitoh H, Horie H, Aoki-Ohmura C, Yamauchi J, Tanaka A, Matsugi J, et al. 2019. Oncogenic Ras mutant causes the hyperactivation of NF-κB via acceleration of its transcriptional activation. Mol Oncol. 13(11):2493−2510.
Terzic J, Grivennikov S, Karin E, Karin M. 2010. Inflammation and colon cancer. Gastroenterology. 138(6):2101−2114.e5.
Wan G, Xie M, Zhang X, Li M. 2019. Chang-wei-qing, a Chinese herbal formula, ameliorates colitis-associated tumor development via inhibiting NF-κB and STAT3 signaling pathway. Pharm Biol. 57(1):231−237.
Wang Y, Li Z, Xu S, Guo J. 2020. Novel potential tumor biomarkers: Circular RNAs and exosomal circular RNAs in gastrointestinal malignancies. J Clin Lab Anal. 34(7):e23339.
West NR, McCuaig S, Franchini F, Powrie F. 2015. Emerging cytokine networks in colorectal cancer. Nat Rev Immunol. 15(10):615−618.
Yahyavour P, Arini P, Rezapour S, Cheki M, Rezaeyan A, Farhood B, Shabead B, Musa AE, Fallah H, Najafi M. 2018. Radiation-induced inflammation and autoimmune diseases. Mil Med Res. 5(1):9−17.
Yang L-J, Jeng C-J, Kung H-N, Chang C-C, Wang A-G, Chau G-Y, Don M-J, Chau Y-P. 2005. Tanshinone IIA isolated from *Salvia miltiorrhiza* elicits the cell death of human endothelial cells. J Biomed Sci. 12(2):347–361.

Yu LCH. 2018. Microbiota dysbiosis and barrier dysfunction in inflammatory bowel disease and colorectal cancers: exploring a common ground hypothesis. J Biomed Sci. 25(1):79.

Zhang X, Wang Y, Ma Z, Liang Q, Tang X, Hu D, Tan H, Xiao C, Gao Y. 2015. Tanshinone IIA ameliorates dextran sulfate sodium-induced inflammatory bowel disease via the pregnane X receptor. Drug Des Devel Ther. 9:6343–6362.

Zhang Y, Ge T, Xiang P, Zhou J, Tang S, Mao H, Tang Q. 2019. Tanshinone IIA reverses oxaliplatin resistance in human colorectal cancer via inhibition of ERK/Akt signaling pathway. Onco Targets Ther. 12:9725–9734.

Zhao Q, Bi Y, Zhong J, Ren Z, Liu Y, Jia J, Yu M, Tan Y, Zhang Q, Yu X, et al. 2020. Pristimerin suppresses colorectal cancer through inhibiting inflammatory responses and Wnt/β-catenin signaling. Toxicol Appl Pharmacol. 386:114813.

Zhou D, Jin J, Liu Q, Shi J, Hou Y. 2019. PPARα agonist enhances colitis-associated colorectal cancer. Eur J Pharmacol. 842:248–254.